Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy

Dizal grants AstraZeneca worldwide rights to develop and commercialise Zegfrovy Dizal will receive an upfront payment of $600M, and milestone payments of up to $900M. Additionally, Dizal will receive tiered royalties on the global sales of Zegfrovy. SHANGHAI, July 14, 2026 /PRNewswire/ --...